Naoero vs Tonga: Hepatitis B surface antigen (HBsAg) prevalence
Naoero
0.6%
in 2024
Tonga
0.6%
in 2024
Naoero rank
51st
Tonga rank
51st
Hepatitis B surface antigen (HBsAg) prevalence over time
- Naoero
- Tonga
How they compare
Naoero currently reports 0.6% against 0.6% in Tonga, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was Naoero ahead.
Naoero ranks 51st and Tonga ranks 51st of 194 countries.
Across the 2 decades both report, Naoero averaged higher in 1 and Tonga in 1.
Head to head by decade
| Decade | Naoero | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.2% | 1.1% | 0.1% | Naoero |
| 2020s | 0.7% | 0.7% | 0.1% | Tonga |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Naoero or Tonga?
- Naoero, at 0.6% against 0.6% in Tonga as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Naoero and Tonga?
- 0.0%, with Naoero ahead.
- How many years of comparable data are there for Naoero and Tonga?
- 10 years are reported by both, from 2015 to 2024.
- How do Naoero and Tonga rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Naoero ranks 51st and Tonga ranks 51st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.